Circulating CLL cells can also express pre‐activated VLA‐4 as a consequence of BCR‐autonomous triggering, further enhancing the binding of the serum VCAM‐1 and the subsequent survival effects [127]. This evidence concerns the gene VCAM1 and B-cell chronic lymphocytic leukemia.